Logan Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Logan Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-29,872	Closed	-$21K	–	507
2020 Q4	$21K	Hold	29,872	–	–	﹤0.01%	302
2020 Q3	$67K	Hold	29,872	–	–	﹤0.01%	353
2020 Q2	$107K	Hold	29,872	–	–	0.01%	285
2020 Q1	$113K	Hold	29,872	–	–	0.01%	303
2019 Q4	$89K	Buy	+29,872	New	+$77.7K	﹤0.01%	296

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Logan Capital Management's BMY.RT Position: Q1 2021 in Review

Logan Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 29,872 shares — an estimated $21K sold.

Logan Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $113K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Logan Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Logan Capital Management sold 29,872 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $21K.
Logan Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Logan Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $113K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Logan Capital Management's 13F filing for Q1 2021, filed 14 May 2021.